Fusion proteins and combination vaccines comprising Haemophilus influenzae Protein E and Pilin A

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) a...

Full description

Saved in:
Bibliographic Details
Main Authors Labbe, Steve, Poolman, Jan, Blais, Normand
Format Patent
LanguageEnglish
Published 14.12.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); andc) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
Bibliography:Application Number: US202016922112